Larissa

Running trials

• Active, not recruiting

  An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

  NCT07517263· Phase 3· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

  NCT07225504· Phase 3· Source

• Recruiting

  Kesimpta (Ofatumumab) in Greek Multiple Sclerosis Patients - an Observational Study

  NCT06486779· Source

• Active, not recruiting

  Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

  NCT05030428· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Multiple sclerosis2 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab

  NCT04353492· Phase 3· Source

• Completed

  Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD

  NCT04023552· Phase 3· Source

• Terminated

  A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).

  NCT03946670· Phase 2· Source

• Completed

  Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)

  NCT01698905· Phase 2· Source